Price
Frequently asked questions
What is Corcept's market capitalization?
What is Corcept's Price-to-Earnings (P/E) ratio?
What is the Earnings Per Share (EPS) for Corcept?
What are the analyst ratings and target price for Corcept's stock?
What is Corcept's revenue over the trailing twelve months?
What is the EBITDA for Corcept?
What is the free cash flow of Corcept?
What is the 5-year beta of Corcept's stock?
How many employees does Corcept have, and what sector and industry does it belong to?
What is the free float of Corcept's shares?
Financials
Market Cap
$6.05B5Y beta
0.51EPS (TTM)
$1.27Free Float
92.70MP/E ratio (TTM)
45.51Revenue (TTM)
$628.56MEBITDA (TTM)
$144.50MFree Cashflow (TTM)
$143.02MPricing
Analyst Ratings
The price target is $49.70 and the stock is covered by 5 analysts.
Buy
5
Hold
0
Sell
0
Information
Corcept Therapeutics Incorporated is a commercial-stage company, which is engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, exicorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
352
Biotechnology & Drugs
Health Care
Identifier
ISIN
Primary Ticker